OncoMatch/Clinical Trials/NCT04817956
Improving Public Cancer Care by Implementing Precision Medicine in Norway
Is NCT04817956 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Atezolizumab for cancer metastatic.
Treatment: Atezolizumab — IMPRESS-Norway is a prospective, non-randomized clinical trial evaluating efficacy of commercially available, anti-cancer drugs prescribed for patients with advanced cancer diagnosed with potentially actionable alterations as revealed by molecular diagnostics. IMPRESS-Norway is a nation-wide study and all hospitals with an oncology and / or hematology department will be invited to participate in the study. The study will use a combined umbrella and basket design and a Simon two-stage model of expanding cohorts to follow up potentially effective combinations of biomarker and drug on specific indications. Sampling of biological material will be performed at presentation, during treatment and upon progression. Additional biomarker and translational analyses including whole genome sequencing (WGS) on tumour material and liquid biopsies, identifying mechanisms underlying drug sensitivity versus resistance will be performed.
Check if I qualifyExtracted eligibility criteria
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: selected study drug
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.5 x10^9 / L; Hemoglobin > 9 g/dl; Platelets > 75,000/µl
Kidney function
Calculated or measured creatinine clearance ≥ 40 mL/min/1.73 m2
Liver function
Total bilirubin < 1.5 x institutional ULN; AST (SGOT) and ALT (SGPT) < 2.5 x ULN (or < 5 x ULN in patients with known hepatic metastases)
Absolute neutrophil count ≥ 1.5 x109 / L; Hemoglobin > 9 g/dl; Platelets > 75,000/µl; Total bilirubin < 1.5 x institutional upper limit of normal (ULN); AST (SGOT) and ALT(SGPT) < 2.5 x institutional upper limit of normal (ULN) (or < 5 x ULN in patients with known hepatic metastases); Calculated or measured creatinine clearance ≥ 40 mL/min/1.73 m2.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify